Monday, March 23, 2020 7:17:03 AM
Watch out for more offerings out of the blue
Recent AYTU News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/03/2026 09:08:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2026 09:05:35 PM
- Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results • ACCESS Newswire • 02/03/2026 09:05:00 PM
- Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 • ACCESS Newswire • 01/27/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 09:05:29 PM
- Aytu BioPharma Recaps Investor Day Held on January 20, 2026 • ACCESS Newswire • 01/20/2026 09:05:00 PM
- Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA • ACCESS Newswire • 01/20/2026 02:00:00 PM
- Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 • ACCESS Newswire • 01/13/2026 09:15:00 PM
- Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City • ACCESS Newswire • 01/12/2026 01:00:00 PM
- Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City • ACCESS Newswire • 12/18/2025 02:00:00 PM
- Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults • ACCESS Newswire • 12/15/2025 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/10/2025 09:05:23 PM
- Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference • ACCESS Newswire • 11/24/2025 09:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2025 06:26:30 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 09:11:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:08:28 PM
- Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results • ACCESS Newswire • 11/13/2025 09:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:35:20 PM
- Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025 • ACCESS Newswire • 11/05/2025 09:05:00 PM
- Aytu BioPharma Announces Patent Term Extension for EXXUA(TM) • ACCESS Newswire • 10/28/2025 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/24/2025 08:03:13 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/24/2025 08:02:41 PM
- Aytu BioPharma to Present at Upcoming October 2025 Conferences • ACCESS Newswire • 10/10/2025 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/07/2025 08:16:28 PM
The Crypto Company Acquires FRAME Blockchain's Technology, An "Interstate Highway" Liquidity Layer for Crypto Commerce • CRCW • Mar 26, 2026 12:28 PM
Resilient Energy Inc. Enters LOI Negtiations for Second Acquisition; First Acquisition Nears Closing • RENI • Mar 26, 2026 10:30 AM
Alliance Creative Group (ACGX) Releases 2025 Annual Financial and Disclosure Report • ACGX • Mar 26, 2026 8:30 AM
Isiah Enterprises Activates Scalable Materials Platform Targeting $900B+ Global Market Opportunity; Initiates Strategic Partner Alignment Phase • OWPC • Mar 25, 2026 9:07 AM
ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • ECGI • Mar 24, 2026 8:30 AM
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
